%D9%BE%D9%85%D8%AA%D8%B1%DA%A9%D8%B3%DB%8C%D8%AFCategory:PemetrexedPemetrexedPemetrexed%D9%BE%D9%85%D8%AA%D8%B1%DA%A9%D8%B3%DB%8C%D8%AFP%C3%A9m%C3%A9trexedPemetrexed%E3%83%9A%E3%83%A1%E3%83%88%E3%83%AC%E3%82%AD%E3%82%BB%E3%83%89PemetrexedPemetrexedePemetrexedPemetreksedPemetreksed%D0%9F%D0%B5%D0%BC%D0%B5%D1%82%D1%80%D0%B5%D0%BA%D1%81%D0%B5%D0%B4PemetrexedQ415220
about
PARAMOUNT trialReolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapySurvival imProvement in Lung cancEr iNduced by DenOsUmab theRapyNeoadjuvant SHR-1210, or SHR-1210 in Combination With Pemetrexed and Carboplatin in Resectable NSCLCEfficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Recurrent Non-squamous NSCLCPemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation StrategiesAPatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)Pemetrexed Plus Gemcitabine in Renal Cell CancerTrial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is MetastaticTrial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With ChemotherapyTrial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerPhase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCInvestigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid TumorPemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerPemetrexed in Patients With Soft Tissue SarcomaPemetrexed in Patients With Advanced Neuroendocrine TumorsPemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal MetastasesEfficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsA Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and RadiotherapyStudy of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy RegimenDosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary SyndromeTrial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung CancerStudy of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung CancerChemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyA Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerA Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never SmokersA Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung CancerPemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid TumorsComparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠBComparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
P4844
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1)Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case reportPemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro studyPemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six casesPrediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profilesQ64073264Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancerClinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasisFGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cellsThird generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCSecond-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma[Pemetrexed salvage chemotherapy for NSCLC: implementation study]A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Pemetreksed
@sh
Pemetreksed
@sr
Pemetrexed
@de
Pemetrexed
@hu
Pemetrexed
@nl
Pemetrexed
@ro
Pemetrexed
@ru
Pemetrexed
@vi
aviario
@it
pemetreksed
@nn
type
label
Pemetreksed
@sh
Pemetreksed
@sr
Pemetrexed
@de
Pemetrexed
@hu
Pemetrexed
@nl
Pemetrexed
@ro
Pemetrexed
@ru
Pemetrexed
@vi
aviario
@it
pemetreksed
@nn
altLabel
Alimta
@ja
Alimta®
@en
C20H21N5O6
@ja
LY-231514
@en
Pemetrexed
@en
pemetrexed
@nn
アリムタ
@ja
ペメトレキセドナトリウム水和物
@ja
prefLabel
Pemetreksed
@sh
Pemetreksed
@sr
Pemetrexed
@de
Pemetrexed
@hu
Pemetrexed
@nl
Pemetrexed
@ro
Pemetrexed
@ru
Pemetrexed
@vi
aviario
@it
pemetreksed
@nn